These Were Big Pharma’s Biggest Winners and Losers in 2016

Biopharma stocks endured a precipitous decline over the course of 2016. But some giants drug making giants made out far better than others, according to a new report based on data from analytics firm Evaluate. To be clear: this analysis is based on market capitalization, and not other critical measures such as clinical trial failures…


Author: MA Consultancy / WelshBiz

Web Marketing Agency & UK Business and Sports News Blogger via regional and national business and sports news blogs and linked social media accounts.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s